Anticancer drug development guide preclinical screening clinical trials and approval 2nd Edition by Beverly A Teicher, Paul A. Andrews – Ebook PDF Instant Download/Delivery: 978-1468498417, 1468498417
Full download Anticancer drug development guide preclinical screening clinical trials and approval 2nd Edition after payment

Product details:

ISBN 10: 1468498417

ISBN 13: 978-1468498417

Author: Beverly A Teicher, Paul A. Andrews

This unique volume traces the critically important pathway by which a “molecule” becomes an “anticancer agent. ” The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these “anticancer” molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute’s high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of “antileukemia” agents, but that other tumor models would be needed to discover drugs active against solid tumors.

Front Matter
High-Volume Screening – Michel Pagé
High-Throughput Screening in Industry – Michael D. Boisclair, David A. Egan, Kety Huberman, Ralph Infantino
The NCI Human Tumor Cell Line (60-Cell) Screen – Michael R. Boyd
Human Tumor Screening – Axel-R. Hanauske, Susan G. Hilsenbeck, Daniel D. Von Hoff

In Vivo Methods

Front Matter
Murine L1210 and P388 Leukemias – William R. Waud
In Vivo Methods for Screening and Preclinical Testing – Thomas Corbett, Lisa Polin, Patricia LoRusso, Fred Valeriote, Chiab Panchapor, Susan Pugh et al.
Human Tumor Xenograft Models in NCI Drug Development – Michael C. Alley, Melinda G. Hollingshead, Donald J. Dykes, William R. Waud
NCI Specialized Procedures in Preclinical Drug Evaluations – Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Christine M. Pacula-Cox, Sherman F. Stinson
Patient-Like Orthotopic Metastatic Models of Human Cancer – Robert M. Hoffman
Preclinical Models for Combination Therapy – Beverly A. Teicher
Models for Biomarkers and Minimal Residual Tumor – Beverly A. Teicher
Spontaneously Occurring Tumors in Companion Animals as Models for Drug Development – David M. Vail, Douglas H. Thamm

Nonclinical Testing to Support Human Trials

Front Matter
Nonclinical Testing – Denis Roy, Paul A. Andrews
Nonclinical Testing for Oncology Drug Products – Paul A. Andrews, Denis Roy
Nonclinical Testing for Oncology Biologic Products – Carolyn M. Laurençot, Denis Roy, Paul A. Andrews

Clinical Testing

People also search for:

anticancer drugs example

anticancer drugs list pdf

anticancer drugs impact factor

anticancer drug development

anticancer drug development strategies

Tags: Beverly A Teicher, Paul Andrews, Anticancer drug, development guide, screening clinical

Anticancer drug development guide preclinical screening clinical trials and approval 2nd Edition by Beverly A Teicher, Paul Andrews ISBN 978-1468498417 1468498417

Table of contents:

People also search for:

Anticancer drug development guide preclinical screening clinical trials and approval 2nd Edition by Beverly A Teicher, Paul Andrews ISBN 978-1468498417 1468498417

Table of contents:

People also search for:

Login